Drug Trial Radar · NCT03931681
A Study of OKI-179 in Patients With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
May 8, 2019
Primary completion
Nov 27, 2021
Study completion Nov 27, 2021
Sponsor
- Lead sponsor
- OnKure, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- University of Colorado, Denver
- First posted
- Apr 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 1, single center, open-label study, assessing single agent dose escalation of OKI-179.
Conditions
- Advanced Solid Tumors
Interventions
OKI-179Drug
OKI-179 single agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D)Time frame: 2 years
- Determine the safety of the drug according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Colorado Cancer Center
Aurora, Colorado
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.